David Kroin
CIK 1397513 · last filed 2026-08-10
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
INFU price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
200 GREENWICH AVENUE, 3RD FLOOR
GREENWICH, CT 06830
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| ATTO | 10%+ Owner | 1,957,138 | $16.88 | $33.04M | $0 | 1 | 2026-08-10 |
| Foamix Pharmaceuticals Ltd. (FOMX) Delisted | 4,781,708 | — | — | $0 | 1 | 2018-09-14 | |
| INFU | 10%+ Owner | 0 | $15.28 | $0 | -$10.15M | 1 | 2011-02-10 |
| ALBIREO PHARMA, INC. (BIOD) Delisted | Director | 94,059 | — | — | -$5.74M | 39 | 2010-03-03 |
| MEMY | 10%+ Owner | 4,765,908 | $13.58 | $64.72M | -$24.9K | 1 | 2008-12-11 |
Recent Filings · Page 3 of 5
43 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2009-08-12 | ALBIREO PHARMA, INC. (BIOD) Delisted | Sell (S) | −4,400 | -$22.1K | EDGAR |
| 2009-08-10 | ALBIREO PHARMA, INC. (BIOD) Delisted | Sell (S) | −7,679 | -$38.9K | EDGAR |
| 2009-08-06 | ALBIREO PHARMA, INC. (BIOD) Delisted | Sell (S) | −7,700 | -$38.6K | EDGAR |
| 2009-08-04 | ALBIREO PHARMA, INC. (BIOD) Delisted | Sell (S) | −1,700 | -$8.5K | EDGAR |
| 2009-07-31 | ALBIREO PHARMA, INC. (BIOD) Delisted | Sell (S) | −13,700 | -$69.3K | EDGAR |
| 2009-07-29 | ALBIREO PHARMA, INC. (BIOD) Delisted | Sell (S) | −12,400 | -$64.5K | EDGAR |
| 2009-07-27 | ALBIREO PHARMA, INC. (BIOD) Delisted | Sell (S) | −78,955 | -$411.8K | EDGAR |
| 2009-07-23 | ALBIREO PHARMA, INC. (BIOD) Delisted | Sell (S) | −50,830 | -$265.6K | EDGAR |
| 2009-07-21 | ALBIREO PHARMA, INC. (BIOD) Delisted | Sell (S) | −7,284 | -$36.8K | EDGAR |
| 2009-07-17 | ALBIREO PHARMA, INC. (BIOD) Delisted | Sell (S) | −9,237 | -$46.2K | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.